Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Дата публикации: 22-06-2026 23:07:28

RAHWAY, N.J.--(BUSINESS WIRE) June 22, 2026 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy	0	12.6	21-07-2026
2	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	0	12.36	14-06-2026
3	Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development	0	17.54	24-07-2026
4	Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies	0	22.47	16-07-2026
5	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)	0	16.04	06-08-2026
6	Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension	0	10.41	23-06-2026
7	New Drug Application for Neladalkib in TKI Pre-Treated Advanced ALK-Positive NSCLC Accepted for Filing with Priority Review by the FDA	0	17.4	27-05-2026
8	Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation	0	12.26	31-07-2026
9	Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer	0	17.15	20-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 18.81. Источник: www.drugs.com.